Increased survival in B-cell-deficient mice during experimental cerebral malaria suggests a role for circulating immune complexes by DeOliveira, Rosane B. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Infectious Diseases and Immunology 
Publications Infectious Diseases and Immunology 
2014-03-18 
Increased survival in B-cell-deficient mice during experimental 
cerebral malaria suggests a role for circulating immune 
complexes 
Rosane B. DeOliveira 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/infdis_pp 
 Part of the Immunity Commons, Immunology of Infectious Disease Commons, Infectious Disease 
Commons, and the Microbiology Commons 
Repository Citation 
DeOliveira RB, Wang JP, Ram S, Gazzinelli RT, Finberg RW, Golenbock DT. (2014). Increased survival in B-
cell-deficient mice during experimental cerebral malaria suggests a role for circulating immune 
complexes. Infectious Diseases and Immunology Publications. https://doi.org/10.1128/mBio.00949-14. 
Retrieved from https://escholarship.umassmed.edu/infdis_pp/361 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Infectious Diseases 
and Immunology Publications by an authorized administrator of eScholarship@UMMS. For more information, 
please contact Lisa.Palmer@umassmed.edu. 
Increased Survival in B-Cell-Deficient Mice during Experimental
Cerebral Malaria Suggests a Role for Circulating Immune Complexes
Rosane B. de Oliveira, Jennifer P. Wang, Sanjay Ram, Ricardo T. Gazzinelli, Robert W. Finberg, Douglas T. Golenbock
R.W.F. and D.T.G. contributed equally to this article.
ABSTRACT The pathogenesis of malaria, an insect-borne disease that takes millions of lives every year, is still not fully under-
stood. Complement receptor 1 (CR1) has been described as a receptor for Plasmodium falciparum, which causes cerebral ma-
laria in humans. We investigated the role of CR1 in an experimental model of cerebral malaria. Transgenic mice expressing hu-
man CR1 (hCR1) on erythrocytes were infected with Plasmodium berghei ANKA and developed cerebral malaria. No difference
in survival was observed in hCR1mice compared to wild-type mice following infection with P. berghei ANKA; however, hCR1
detection was significantly diminished on erythrocytes between days 7 and 10 postinfection. hCR1 levels returned to baseline by
day 17 postinfection in surviving animals. Immunoblot assays revealed that total erythrocyte hCR1 levels were diminished, con-
firming that immune complexes in association with erythrocyte hCR1 were likely removed from erythrocytes in vivo by clear-
ance following immune adherence. Decreases in hCR1 were completely dependent on C3 expression, as mice treated with cobra
venom factor (which consumes and depletes C3) retained hCR1 on erythrocytes during C3 depletion through day 7; erythrocyte
hCR1 decreases were observed only when C3 levels recovered on day 9. B-cell-deficient mice exhibit a marked increase in sur-
vival following infection with P. berghei ANKA, which suggests that immune complexes play a central role in the pathogenesis of
experimental cerebral malaria. Together, our findings highlight the importance of complement and immune complexes in ex-
perimental cerebral malaria.
IMPORTANCE Cerebral malaria is a deadly complication of infection with Plasmodium falciparum. Despite its high prevalence,
relatively little is understood about its pathogenesis. We have determined that immune complexes are generated and deposited
on erythrocytes specifically expressing human complement receptor 1 in a mouse model of cerebral malaria. We also provide
evidence demonstrating the importance of immunoglobulins in the pathogenesis of cerebral malaria in mice. These findings may
have important implications in human cerebral malaria.
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Approximately half of the world’s population is at risk of ma-laria. According to World Health Organization estimates,
malaria infects more than 200 million people worldwide each
year, kills over 600,000 people, and is a public health issue in more
than 90 countries (http://www.who.int/malaria/media/world
_malaria_report_2013). Annual deaths from malaria may in fact
be twice as high (1). The incubation period of malaria ranges from
9 to 14 days for Plasmodium falciparum. Symptoms of malaria
include fever, chills, headache, fatigue, muscular pains, mild diar-
rhea, nausea, and vomiting and can be mistaken for influenza or
gastrointestinal infection. Cerebral malaria and severe malarial
anemia are two complications of P. falciparum infection. Malaria
can lead to impairment of brain or spinal cord function, seizures,
or loss of consciousness. Cerebral malaria death is not well under-
stood (2, 3). Heavy parasite sequestration and extravascular path-
ological findings in the brain, retina, gastrointestinal tract, and
subcutaneous fat are seen with cerebral malaria (4–6). The under-
standing of cerebral malaria is limited because of the low fre-
quency of autopsies in most areas in which malaria is endemic.
Severe anemia occurs during the P. falciparum blood stage due to
an increase in clearance of uninfected cells and a failure of an
adequate bone marrow response. The degree of anemia also de-
pends on the immune status of the patient, nutritional back-
ground, and other complicating factors (7–10).
Murine infections with Plasmodium species are widely used as
surrogate models to study malaria. Mouse models of malaria are
clearly divided into two groups, those resistant to and those sus-
ceptible to cerebral disease (11, 12). Certain strains of mice in-
fected with Plasmodium berghei ANKA exhibited neurological
signs, sharing characteristics with human cerebral malaria (13).
Parasitized red cells are responsible for lesions in various organs in
humans and can also be found in different organs in mice (6,
14–17). While cell-mediated immunity protects against the para-
site, an imbalance in immune responses may contribute to the
pathogenesis of human cerebral malaria (18). As an example, a
robust humoral response with high serum levels of IgG and IgM
antibodies can result in the deposition of immune complexes and
can contribute to inflammation in cerebral microvessels (19).
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The role of the complement system in the pathogenesis of sev-
eral diseases has been increasingly recognized (20–24). Comple-
ment proteins or receptors may modulate the course of malaria in
distinct ways. C5/ mice have a slight survival advantage in ce-
rebral malaria (25), while others found that C3/ mice have no
survival advantage (26). Hematin has been shown to activate the
alternative pathway on erythrocytes (27). Human complement
receptor 1 (hCR1) has been reported to serve as a receptor for
Plasmodium falciparum invasion via direct binding of the parasite
ligand (28). Erythrocyte CR1 is also involved in the rosette forma-
tion of uninfected erythrocytes with P. falciparum-infected eryth-
rocytes (29). CR1 plays an important role in the control of com-
plement activation and also serves as the “immune adherence
receptor” to facilitate clearance of immune complexes (ICs), as
IC-coated erythrocytes traverse macrophage-lined liver and
spleen sinusoids. ICs activate complement, which results in the
deposition of C3 and C4 fragments on the ICs. By virtue of its
ability to bind to C3 and C4 fragments, erythrocyte CR1 binds to
complement-coated ICs, and CR1 and complement-coated ICs
together are cleared from the circulation as erythrocytes traverse
the liver and spleen. Following removal of complement-coated
ICs and CR1, erythrocytes return to the circulation. ATP release
by the IC-coated erythrocyte may promote CR1 clustering to in-
crease avidity of binding of complement-coated ICs with CR1 and
also facilitate the phagocytosis of immune-adherent ICs (30).
We investigated whether murine models of Plasmodium infec-
tion could be used to address the roles of complement, ICs, and
erythrocyte CR1 during malaria. Because normal murine erythro-
cytes do not express CR1, we employed transgenic mice that ex-
press hCR1 on their erythrocytes (31) to elucidate the role of hu-
man erythrocyte CR1 and circulating immune complexes (CICs)
during experimental cerebral malaria. We found that infecting
either wild-type or human CR1 transgenic mice with P. berghei
ANKA results in equal rates of lethal cerebral malaria. Strikingly, a
transient but reproducible reduction in erythrocyte CR1 levels is
observed following infection. We sought to determine the mech-
anism by which this decrease in erythrocyte CR1 occurs.
RESULTS
The presence of erythrocyte CR1 does not influence the disease
course in murine malaria. Infections with P. berghei ANKA are
typically established by an intraperitoneal injection of 104 to 105
infected erythrocytes simultaneously exhibiting all of the parasite
developmental stages in the blood. Experimental cerebral malaria
(ECM) develops in susceptible mice between 6 and 8 days postin-
fection and is a major cause of mortality. Following infection with
105 infected erythrocytes, the following signs of cerebral malaria
were used to score disease severity in wild-type C57BL/6 and
hCR1 transgenic (hCR1) mice: ruffled fur, abnormal posture,
disturbances in balance, limb paralysis, convulsion, coma, and
death. No significant differences were observed in either morbid-
ity or survival in hCR1 mice versus wild-type mice (Fig. 1) or
FIG 1 Transgenic hCR1 mice infected with Plasmodium berghei ANKA develop parasitemia and cerebral malaria. (A) hCR1mice and wild-type mice equally
succumbed to cerebral malaria infection. hCR1mice (n 20) and wild-type mice (n 20) were intraperitoneally infected with 105 P. berghei ANKA-infected
erythrocytes and monitored for survival. Animals with severe cerebral malaria were sacrificed by CO2 asphyxiation. (B) Parasitemia levels were comparable
between hCR1 mice and wild-type C57BL/6 mice following infection with P. berghei ANKA. Parasitemia was assessed every 2 to 4 days by microscopy of
Giemsa-stained thin blood smears or by flow cytometry using a monoclonal antibody against TER-119 at 1:100 and ethidium bromide to stain the nuclei
(parasites). Representative scatter plots from day 7 postinfection are shown for wild-type and hCR1 animals. The x axis shows FITC (TER-119), and the y axis
shows ethidium bromide (parasites).
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disease severity (data not shown). In addition, parasitemia levels
were similar between hCR1 and wild-type mice (Fig. 1B). Eryth-
rocytes were monitored by expression of the TER-119 antigen, a
52-kDa glycophorin A-associated protein that is expressed from
the early proerythroblast stage to mature erythrocytes (32), and
parasites were stained with ethidium bromide according to previ-
ously published methods (33).
hCR1 on erythrocytes decreases after mice are infected with
P. berghei ANKA. Flow cytometric analysis of hCR1 levels during
the course of P. berghei ANKA infection revealed an apparent loss
of CR1 expression on erythrocytes that is greatest between 7 and
10 days postinfection, though some decreases can be detected as
early as day 5 postinfection (Fig. 2A). Detection of hCR1 was re-
stored by day 17 postinfection in surviving mice. By day 17, the
presence of a second high-CR1-staining peak suggested that new
erythrocytes entered the circulation during infection, likely in re-
sponse to infection-related anemia (Fig. 2A). The average values
of hCR1 detected in mice through day 25 following infection are
plotted in Fig. 2B. As expected, some animals succumbed to dis-
ease over time.
To ensure that the diminished erythrocyte CR1 levels observed
by flow cytometry were not the result of ICs binding to CR1,
thereby restricting access of the anti-CR1 antibody to its epitope
on CR1, we performed immunoblotting assays on erythrocytes
from hCR1 mice infected with P. berghei ANKA. Decreases in
hCR1 were observed at day 9 postinfection compared to baseline
(day 0) (Fig. 3). hCR1 levels rose significantly by day 15 postinfec-
tion compared to baseline levels in surviving mice, which corre-
spond to the flow cytometry data observations (Fig. 2A) and could
be attributed to new erythrocyte generation.
Decreases in hCR1 following P. berghei ANKA infection are
dependent on C3. hCR1 binds to C3b via its long homologous
repeat B (LHR-B) and LHR-C, which facilitate the clearance of
complement-coated immune complexes (“immune adherence”-
mediated clearance). Thus, we sought to establish if the apparent
decrease in hCR1 during P. berghei ANKA infection would occur
in the absence of C3. Treatment of mice with cobra venom factor
(CoVF) leads to a decrease in C3 with a nadir observed approxi-
mately 24 h postinjection. A single therapeutic dose of CoVF re-
sults in low hemolytic activity for 4 to 6 days (34) and low C3 levels
for 5 to 8 days (35). To maximize C3 depletion for as long a time as
possible in this experimental system, we used four doses of CoVF,
FIG 2 Infection of hCR1 mice with P. berghei ANKA results in diminished
detection of hCR1 on erythrocytes at 7 to 10 days postinfection. (A) Flow
cytometry histograms from an experiment with one representative wild-type
and two representative hCR1mice that survived 25 days following P. berghei
ANKA infection are shown over a time course. Freshly isolated erythrocytes
from infected or uninfected mice were analyzed on days 0, 5, 7, 9, 10, 17, and
25. The expression of cell surface hCR1 was analyzed. The histograms show the
fluorescence intensity of erythrocyte CR1 detected (the x axis indicates FITC or
CR1, and the y axis represents the percentage of the maximum); 1 105 cells
were analyzed in each event. Percent parasitemia of each mouse, also measured
by flow cytometry (data not shown), is indicated with asterisks. (B) Average
values of CR1 detection for each time point for available mice are shown. Error
bars indicate the standard errors of the means.
FIG 3 hCR1mice had decreased protein levels of erythrocyte hCR1 at day 7
after infection with P. berghei ANKA. (A) Representative immunoblots of CR1
and TER-119 in erythrocytes from hCR1 mice infected with P. berghei
ANKA. CR1 bands (200 kDa) were quantified by densitometry and normalized
to TER-119 (52 kDa). Decreases in hCR1 normalized to TER-119 were ob-
served at day 9 postinfection relative to baseline (day 0). CR1 levels rose sig-
nificantly by day 15 compared to baseline. A second independent experiment
revealed decreases in erythrocyte CR1 in three mice at day 7 compared to
baseline (day 0). (B) Densitometry ratios of CR1 to TER-119, relative to day 0
baseline values.
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with the knowledge that CoVF is highly immunogenic and anti-
bodies elicited after a week will block CoVF activity (34). We
found that control hCR1mice not treated with CoVF showed the
typical decline in erythrocyte hCR1 levels at day 7 after infection
with P. berghei ANKA, whereas hCR1 mice treated with CoVF
did not show decreased erythrocyte hCR1 levels until day 9 postin-
fection. Average hCR1 levels are plotted in Fig. 4; individual his-
tograms are shown in Fig. S1 in the supplemental material.
Circulating immune complexes are detected during the
course of infection of P. berghei ANKA. We next confirmed the
presence of ICs in serum during the course of P. berghei ANKA
infection. Serum samples from wild-type and hCR1 mice were
collected at days 8 and 10 postinfection. In both wild-type and
transgenic mice, CICs peaked at day 8 and began to decline at day
10 (Fig. 5). This was consistent with the data above and suggested
that CICs bind to erythrocyte CR1 between days 7 and 10 postin-
fection. At day 10, the IgG and IgM levels were significantly lower
in hCR1mice than in wild-type mice, presumably because CICs
are cleared more rapidly in these animals.
B-cell-deficient mice display increased survival following P.
berghei ANKA infection. In light of our findings suggesting that
ICs formed during ECM and were associated with hCR1 on eryth-
rocytes, we sought to determine if IC formation impacts survival
of mice infected with P. berghei ANKA. Thus, we infected wild-
type C57BL/6 and B-cell-deficient mice, which lack mature B cells
and cannot generate immunoglobulins (36), with P. berghei
ANKA and monitored survival in four independent experiments.
The combined results of these four studies, each of which inde-
pendently demonstrated significance, are shown in Fig. 6A. The
B-cell-deficient mice had significantly increased survival, with a
median survival of 12.5 days compared to 10 days in wild-type
mice (P 0.0001; 2 47.18, log rank test). Multiple cohorts did
not result in any confounding effect, as unadjusted and adjusted
hazard ratios from the Cox model were similar. Only 2% of wild-
type mice (1 of 44) escaped cerebral malaria, versus 50% of B-cell-
deficient mice (21 of 42). Histopathologic analysis of brains of
moribund, infected B-cell-deficient mice revealed distinct micro-
vascular lesions (Fig. 6B). The most striking observation was that
blood vessels of B-cell-deficient mice had significant leukocyte
plugging and cellular infiltration with minimal hemorrhage. In
contrast, wild-type mice consistently had moderate hemorrhage
with minimal leukocyte plugging of the microvasculature. Vascu-
lar lesions were similar in number and distribution between wild-
type and B-cell-deficient mice. Infected red blood cells (iRBCs)
were present in both groups without significant differences in par-
asitemia at day 11 postinfection; levels in wild-type mice were 25%
 2% (n 16) and levels in B-cell-deficient mice were 23% 1%
(n 16). Of note, B-cell-deficient mice exhibited distinct signs of
illness at terminal stages of disease. These mice did not have the
convulsions typically seen in wild-type mice with ECM. B-cell-
deficient mice presented with hind limb paralysis during end-
FIG 4 Treatment with cobra venom factor delays the kinetics of hCR1 de-
cline. hCR1 mice were infected with P. berghei ANKA (PbA) (intraperitone-
ally with 105 infected erythrocytes). Mice were treated with either cobra venom
factor (CoVF, n 4) or saline control (n 4) on the day of infection and on
days 3, 5, and 7 postinfection and monitored for survival. Freshly isolated
erythrocytes from infected or uninfected mice were analyzed on days 0, 3, 6, 7,
and 9. All mice treated with saline control exhibited the characteristic decrease
in erythrocyte CR1 detection on day 7 postinfection by flow cytometry using
antibody 7G9. On day 8 postinfection, these same mice all experienced con-
vulsions and were euthanized. Mice treated with CoVF also had a decrease in
erythrocyte hCR1 detection, but the decrease was delayed until day 9 postin-
fection, which was consistent with the kinetics of CoVF activity. Average values
of CR1 detection for each time point for mice are shown. Error bars indicate
the standard errors of the means. **, P 0.01.
FIG 5 Circulating immune complexes develop during the course of P. berghei
ANKA infection. Immune complexes with IgM (A) or IgG (B) are detected in
sera from infected wild-type (n 6) and hCR1 (n 6) mice at days 8 and 10
after infection with P. berghei ANKA. Levels are significantly lower at day 10
than at day 8 for both wild-type and hCR1mice. In addition, at day 10, levels
are slightly but significantly lower in hCR1 mice than in wild-type mice.
Values for uninfected wild-type and hCR1 mouse sera are shown for refer-
ence. *, P 0.05; ***, P 0.001.
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stage disease, whereas wild-type animals had unilateral hemiple-
gia.
DISCUSSION
We have made several important findings with P. berghei ANKA
ECM in transgenic mice expressing human CR1 on erythrocytes.
We have identified the generation of ICs during P. berghei ANKA
infection, which is accompanied by decreases in erythrocyte hCR1
levels between days 7 and 10 following infection. However, eryth-
rocyte CR1 did not appear to affect parasitemia, disease course, or
survival. The transient decrease in CR1 was detected by flow cy-
tometry and validated by immunoblot assay. In mice that survived
the infection, erythrocyte CR1 levels eventually recovered and sur-
passed baseline levels both by flow cytometry (manifested as a
second peak) and by immunoblot assay, and that recovery prob-
ably is the result of introduction of new erythrocytes into the cir-
culation. The decreased CR1 levels noted by flow cytometry and
by immunoblotting confirm true loss of CR1 from the erythro-
cyte, rather than “masking” of CR1 epitopes for the detecting an-
tibody by ICs. The decreases in erythrocyte CR1 during ECM are
dependent on C3, as demonstrated by the delay in kinetics follow-
ing treatment of mice with CoVF. A schematic of erythrocyte CR1
clearance following immune adherence is shown in Fig. 7.
The role of ICs in the pathogenesis and severity of autoimmune
diseases such as systemic lupus erythematosus is well established.
ICs also contribute to the pathogenesis of several infectious dis-
eases. Examples include IC-mediated vasculitis and renal damage
in streptococcal infections, hepatitis B virus, HIV-1 infection, bac-
terial endocarditis, and cryoglobulinemia associated with hepati-
tis C virus (37). The interplay between erythrocyte CR1 and ICs
could contribute to the complications of malaria. In humans,
polymorphisms can dictate the size (length) and the expression
levels of CR1 on erythrocytes. Four different size variants have
been described (CR1*1 through 4) that result from deletions or
duplications of LHRs during unequal crossover events (38, 39).
The level of CR1 expressed is regulated by the H (high-expression)
and L (low-expression) codominant alleles: LL, HL, and HH ge-
notypes give rise to low, intermediate, and high CR1 expression,
respectively (40). In humans, CR1 levels also vary with age—levels
are high at birth, followed by low levels between 6 and 24 months
of age (41), a period at which children are most susceptible to
malaria.
Complement activation triggered by ICs may precipitate severe
malarial anemia (42), and in this instance, individuals with low
CR1 levels (and therefore with decreased ability to degrade C3b
and C4b to their hemolytically inactive fragments) could conceiv-
ably be at a greater risk of developing severe malarial anemia (43–
45). It is not clear whether the low CR1 levels observed in these
instances are the result of removal of the CR1 from erythrocytes
FIG 6 B-cell-deficient mice display tempered courses of experimental cere-
bral malaria. B-cell-deficient mice were intraperitoneally infected with 105 P.
berghei ANKA-infected erythrocytes and monitored for survival. (A) Survival
was significantly increased for B-cell-deficient mice (n  42) compared to
wild-type mice (n  44) (P  0.0001) (2  47.18 using a log rank test).
Combined data from four independent experiments are shown. (B) B-cell-
deficient mice exhibit morphologically different vascular lesions in brains
compared with those of wild-type mice in experimental cerebral malaria.
Wild-type and B-cell-deficient mice were challenged with P. berghei ANKA
and euthanized on day 9 (wild-type) or day 10 (B-cell-deficient) postinfection,
when animals were moribund. Wild-type mouse brains (upper panels)
showed mild to moderate hemorrhage involving the forebrain and cerebellum
with occasional neuronal cell death. Mild leukocyte plugging of microvascu-
lature was observed. Brains from B-cell-deficient mice (lower panels) had min-
imal to mild hemorrhage with notable leukocyte plugging of the microvascu-
lature. Malarial forms were present in erythrocytes in both wild-type and
B-cell-deficient mice. Sections from seven wild-type and six B-cell-deficient
mice at terminal stages of illness were compared, with consistent findings
within each group. All sections were stained with hematoxylin-eosin. Magni-
fication,400.
FIG 7 Summary figure of immune complex clearance in the P. berghei
ANKA-infected hCR1 transgenic mouse. CIC, circulating immune complex;
hCR1, human complement receptor 1.
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(as we described here in our model) or the result of genetically
determined low CR1 levels. Evidence supporting the former hy-
pothesis stems from a study which showed normalization of CR1
levels following resolution of infection (44). Other studies have
not shown a correlation between severe disease and CR1 levels
(46).
Rosetting, a phenomenon where a specific variant PfEMP1 ex-
pressed by parasitized erythrocytes adheres to CR1 on uninfected
erythrocytes to form clumps, is believed to play a central role in
the pathophysiology of P. falciparum cerebral malaria (29). Roset-
ting was also demonstrated in 14 of 15 clones of Plasmodium cha-
baudi tested in a murine model using wild-type C57BL/6J mice
(47), suggesting that this phenomenon may occur independently
of erythrocyte CR1 in mice. One would expect CR1 polymor-
phisms that are associated with reduced ability to form rosettes
(e.g., Sl2 and Sl2/2) to be associated with a lower incidence of
cerebral malaria, but studies addressing this issue have yielded
conflicting results (48, 49).
ICs have proinflammatory properties, and indeed, studies cur-
rently being carried out by our group have shown that human
peripheral blood mononuclear cells stimulated with ICs isolated
from the serum of individuals with Plasmodium vivax malaria
secrete interleukin-6, tumor necrosis factor, and IL-1 (D. Golen-
bock and R. Gazzinelli, unpublished observations). The loss of
CR1 that we have observed coincides with a rise in IgG- and IgM-
containing ICs and may represent an attempt to clear these pro-
inflammatory complexes from the circulation.
Fernandez-Arias et al. recently reported diminished levels of
surface CR1 on monocytes/macrophages both in a rodent malaria
model and in patients infected with eitherP. falciparum orP. vivax
(50). These data together illustrate the importance of IC deposi-
tion and clearance during malaria infection.
Our data led us to investigate the role of immunoglobulins in
the pathogenesis of ECM. B-cell-deficient mice, devoid of immu-
noglobulins, exhibited increased survival and delayed onset of dis-
ease. Histopathology revealed striking differences, with a lower
degree of microvascular hemorrhage in the B-cell-deficient mice.
To our knowledge, only one other study reports data with P. ber-
ghei ANKA ECM using B-cell-deficient mice having the targeted
deletion in the  region of the IgM locus (also known as B-cell-
null, BKO,MT, or Igh-6null mice). Yañez et al. reported that 3 of
4MT mice and 8 of 8 wild-type mice developed cerebral malaria
in a single experiment; the limited numbers presumably pre-
cluded achieving statistical significance (51). Infections of JHD
mice, which have a targeted deletion of the JH region of the IgM
locus, were more suggestive of a role of B cells in disease; in three
experiments, only 8 of 31 JHD mice developed cerebral malaria,
whereas 24 of 27 wild-type mice developed cerebral malaria (51).
In our studies, the pathological findings of decreased hemorrhage
and increased leukocyte plugging in the microvasculature of
brains of the B-cell-deficient mice with ECM were striking. In
ECM, P. berghei ANKA parasites do not infect the brain paren-
chyma; rather, a fraction of infected erythrocytes accumulates in-
travascularly, including in the brain (52). CD4 and CD8 T cells
have both been implicated in the development of ECM (51, 53–
55). Mice deficient in T cells are ECM resistant and lack microvas-
cular lesions, endothelial cell death, and mononuclear cell infiltra-
tion. It would be interesting to determine if the decreased
hemorrhage in the microvasculature is directly associated with a
lack of IC formation, as this could have important implications for
the pathogenesis of cerebral malaria.
Of note, we did not observe any decreases in hCR1 when
hCR1 transgenic mice were challenged with either P. chabaudi,
which results in parasite clearance, or P. berghei NK65, which
causes severe anemia (data not shown). Disease was comparable
between transgenic and wild-type mice in both infection models
in terms of parasitemia, anemia, and clinical signs. Thus, the de-
creases in erythrocyte CR1 appear to be specific for P. berghei
ANKA infection and/or ECM. Altogether, we propose that CIC
plays a major role in the pathogenesis of ECM and that immuno-
globulin deficiency alters the disease outcome following P. berghei
ANKA infection. Future studies to define the antigenic content of
malarial IC and to determine how ICs may specifically contribute
to microvascular damage and hemorrhage are merited.
MATERIALS AND METHODS
Ethics. All experiments involving animals were in accordance with guide-
lines set by the American Association for Laboratory Animal Science (AA-
LAS). All protocols related to this work were approved by the Institutional
Animal Care and Use Committee (IACUC) at the University of Massa-
chusetts Medical School.
Mice. All mice were bred and maintained under specific-pathogen-
free conditions in the animal facilities at the University of Massachusetts
Medical School in accordance with the University of Massachusetts Med-
ical School’s IACUC. B-cell-deficient mice (IgH6) on the C57BL/6 back-
ground as well as control wild-type C57BL/6 mice were originally pur-
chased from Jackson Laboratories. Transgenic mice expressing human
CR1 on erythrocytes (hCR1) were generated on the C57BL/6 back-
ground as previously described (31). Age- and sex-matched groups of
mice were used in all experiments.
Plasmodium infection. Mice (5 to 10 weeks old) were infected with
the frozen stock of Plasmodium berghei ANKA (gift of A. Luster, Massa-
chusetts General Hospital, Boston, MA). Parasitemia of infected RBCs
(iRBCs) was assessed every 2 or 3 days by microscopy of Giemsa-stained
thin blood smears, and 7 to 8 days later, when the parasitemia showed
mostly ring stages and the mice suffered from cerebral malaria symptoms,
blood was drawn and used for infection studies.
Wild-type, transgenic, and knockout mice were each infected with 105
iRBCs in 200l phosphate-buffered saline (PBS) by intraperitoneal injec-
tion. Survival and signs of disease were monitored daily. Animals that
showed neurological signs, such as convulsions, ataxia, and paralysis, fol-
lowed by death, between 7 and 12 days after infection were considered to
have cerebral malaria (56). Whole blood was collected periodically in
hirulin for assessment of CR1.
Cobra venom factor treatment. For some experiments, animals re-
ceived either four doses of cobra venom factor (CompTech, Tyler, TX),
each dose at 200 g/kg of body weight, administered intraperitoneally
prior to infection and on days 3, 5, and 7 postinfection to deplete comple-
ment, or sterile normal saline (control animals).
Immunoblot assays. Red blood cell lysates in NuPAGE LDS sample
buffer (4) were separated and then transferred to an Immobilon poly-
vinylidene difluoride (PVDF) membrane (Millipore) (57). Membranes
were blocked with PBS-1% milk and probed with a polyclonal rabbit IgG,
anti-CR1 affinity-purified antibody that was provided by J. P. Atkinson
(Washington University, St. Louis, MO). CR1-reactive bands were de-
tected with goat anti-rabbit IgG conjugated to alkaline phosphatase
(Sigma-Aldrich) followed by the addition of 5-bromo-4-chloro-3-
indolylphosphate and nitroblue tetrazolium (BCIP/NBT)-Purple Liquid
substrate (Promega, Madison, WI). Rat anti-mouse TER-119 antibody
was obtained from eBioscience, and TER-119 bands were detected with
anti-rat IgG-alkaline phosphatase antibody produced in goat (Sigma-
Aldrich).
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Flow cytometry. The relative expression of mouse erythrocyte CR1
was determined using the anti-CR1 monoclonal antibody 7G9 (provided
by Ron Taylor, University of Virginia School of Medicine). Either 7G9 was
directly labeled with Alexa Fluor 647 according to the manufacturer’s
directions (Molecular Probes, Eugene, OR, USA), or a fluorescein isothio-
cyanate (FITC)-labeled secondary antibody was used for detection. The
erythrocyte population was identified by staining with FITC-conjugated
anti-TER-119 antibody. Subsequently, the cells were washed twice, and
100,000 cells were analyzed using an LSRII flow cytometer (BD Biosci-
ence). Data were acquired with DIVA software (BD Bioscience) and ana-
lyzed with FlowJo (Tree Star).
Immune complex ELISA. Plates were coated with purified human
C1q at 5g/ml in PBS overnight at 4°C and then blocked with 1% bovine
serum albumin (BSA) in PBS for 1 h. Serum from infected and uninfected
animals was diluted 1:100 and added for 1 h at 37°C. Captured immune
complexes were detected with anti-mouse IgG and anti-mouse IgM alka-
line phosphatase (1:1,000 dilution in PBS-0.05% Tween 20).
Histopathology. Eight days following P. berghei ANKA infection,
brains were carefully removed and fixed in formaldehyde solution (4%,
vol/vol). Tissue sections were prepared and stained with hematoxylin and
eosin as described elsewhere (9). Slides were reviewed independently by a
veterinary pathologist.
Statistical analysis. All data were analyzed using GraphPad Instat 4.0
software. Unless stated otherwise, all comparisons were performed using
a two-tailed Student t test. Mann-Whitney U testing was used for non-
parametric analysis when data did not fit a Gaussian distribution. A
P value of 0.05 was considered to be statistically significant.
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